MetLife Investment Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-27,220
| Closed | -$428K | – | 2942 |
|
|
2024
Q1 | $428K | Hold |
27,220
| – | – | ﹤0.01% | 1762 |
|
|
2023
Q4 | $439K | Hold |
27,220
| – | – | ﹤0.01% | 1768 |
|
|
2023
Q3 | $346K | Hold |
27,220
| – | – | ﹤0.01% | 1852 |
|
|
2023
Q2 | $383K | Hold |
27,220
| – | – | ﹤0.01% | 1872 |
|
|
2023
Q1 | $421K | Buy |
27,220
+3,752
| +16% | +$62.6K | ﹤0.01% | 1752 |
|
|
2022
Q4 | $385K | Hold |
23,468
| – | – | ﹤0.01% | 1812 |
|
|
2022
Q3 | $434K | Hold |
23,468
| – | – | ﹤0.01% | 1744 |
|
|
2022
Q2 | $309K | Hold |
23,468
| – | – | ﹤0.01% | 2002 |
|
|
2022
Q1 | $218K | Buy |
23,468
+8,328
| +55% | +$70.8K | ﹤0.01% | 2311 |
|
|
2021
Q4 | $148K | Hold |
15,140
| – | – | ﹤0.01% | 2245 |
|
|
2021
Q3 | $514K | Hold |
15,140
| – | – | ﹤0.01% | 1504 |
|
|
2021
Q2 | $554K | Hold |
15,140
| – | – | ﹤0.01% | 1506 |
|
|
2021
Q1 | $679K | Hold |
15,140
| – | – | 0.01% | 1354 |
|
|
2020
Q4 | $864K | Sell |
15,140
-1,458
| -9% | -$86.4K | 0.01% | 1202 |
|
|
2020
Q3 | $851K | Hold |
16,598
| – | – | 0.01% | 1107 |
|
|
2020
Q2 | $991K | Buy |
16,598
+7,876
| +90% | +$421K | 0.01% | 1039 |
|
|
2020
Q1 | $359K | Hold |
8,722
| – | – | ﹤0.01% | 1388 |
|
|
2019
Q4 | $543K | Buy |
8,722
+1,159
| +15% | +$55.1K | 0.01% | 1422 |
|
|
2019
Q3 | $257K | Hold |
7,563
| – | – | ﹤0.01% | 1804 |
|
|
2019
Q2 | $171K | Buy |
+7,563
| New | +$177K | ﹤0.01% | 2128 |
|
|
2018
Q4 | – | Sell |
-3,916
| Closed | -$152K | – | 2601 |
|
|
2018
Q3 | $152K | Buy |
+3,916
| New | +$145K | ﹤0.01% | 2241 |
|
Other funds holding DCPH
MetLife Investment Management's DCPH Position: Q2 2024 in Review
MetLife Investment Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 27,220 shares — an estimated $428K sold.
MetLife Investment Management first reported a position in DCPH in Q3 2018 and held it in 21 quarters. The position peaked at $991K in Q2 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- MetLife Investment Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- MetLife Investment Management sold 27,220 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $428K.
- MetLife Investment Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 21 quarters.
- MetLife Investment Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $991K in Q2 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.